Another patient has received a transplant with a genetically modified pig kidney. Tim Andrews, a 66-year-old who lives in Concord, N.H., has end-stage kidney disease and had been on dialysis for more than two years to compensate for his failing kidney function.

The surgery comes at a turning point in the quest to tell if animal-to-human transplants could help ease the shortage of donated human organs.

It was the fourth pig kidney transplant in the United States, and the first of three that will be done at Mass General as part of a new clinical trial sanctioned by the Food and Drug Administration. Two of the previous patients died shortly after the procedure, including one who was critically ill before the transplant.

A Mass General Hospital surgical team has completed its second pig-to-human kidney transplant, less than a year after the hospital performed the world’s first such surgery.

A team at Massachusetts General Hospital led by Harvard Medical School physician-scientists has for the second time successfully transplanted a genetically edited pig kidney into a living person. The team performed the first surgery of its kind in the world in March 2024.

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys for patients with end-stage renal disease. Study aims to provide alternative for 500,000 Americans on dialysis.

A 66-year-old man, Tim Andrews, has successfully undergone a pig kidney transplant, becoming the second person to do so.